三个皮匠报告
最新
报告分类 研搜
BETA
政策库
自研报告
new
入驻
搜索
您的当前位置：首页 > 行业数据 > 2a期临床试验结果显示，特泽利尤单抗在BEC≥150以及FeNO≥25人群中疗效更好
图片属性
图片格式：PNG 图片大小：396KB 图片尺寸：2346*1175
同报告图片
 / 4
2a期临床试验结果显示，特泽利尤单抗在BEC≥150以及FeNO≥25人群中疗效更好_第1页
fCDpobnnm64gfCBUZXplcGVsdW1hYiBncm91cCAobj0xNjUpIHwgUGxhY2VibyBncm91cCAobj0xNjgpIHwgUmF0ZSByYXRpbyAoOTUlIENJKSB8CnwgLS0tIHwgLS0tIHwgLS0tIHwgLS0tIHwKfCDmgLvkvZMgfCAxNjUvMS43NSB8IDE2OC8yLjExIHwgMC44MyAoMC42MS0xLjExKSB8CnwgQkVDLCBjZWxscyBwZXIgzrxMIHwgIHwgIHwgIHwKfCA8MTUwIHwgNzMvMi4wNCB8IDY0LzEuNzEgfCAxLjE5ICgwLjc1LTEuOTApIHwKfCAxNTAgdG8gPDMwMCB8IDY4LzEuNjQgfCA3Mi8yLjQ3IHwgMC42NiAoMC40Mi0xLjA0KSB8Cnwg4omlMzAwIHwgMjQvMS4yMCB8IDMyLzIuMjQgfCAwLjU0ICgwLjI1LTEuMTUpIHwKfCDlkLjng5/nirblhrUgfCAgfCAgfCAgfAp8IOabvuWQuOeDn+iAhSB8IDExMC8xLjUxIHwgMTE3LzEuOTMgfCAwLjc4ICgwLjU0LTEuMTMpIHwKfCDlvZPliY3lkLjng5/ogIUgfCA1NS8yLjIzIHwgNTEvMi41NyB8IDAuODcgKDAuNTItMS40NSkgfAp8IOS4reS9jeWQuOeDn+aMgee7reaXtumXtO+8jOWMheW5tCB8ICB8ICB8ICB8CnwgPDQ3IHwgNzkvMS42MiB8IDg0LzIuMTQgfCAwLjc1ICgwLjQ5LTEuMTYpIHwKfCDiiaU0NyB8IDg2LzEuODcgfCA4NC8yLjA5IHwgMC45MCAoMC41OS0xLjM2KSB8CnwgRmVOTyDmsLTlubPvvIxwcGIgfCAgfCAgfCAgfAp8IDwyNSB8IDExNy8xLjkzIHwgMTA5LzEuOTQgfCAwLjk5ICgwLjY5LTEuNDMpIHwKfCDiiaUyNSB8IDI2LzEuMTUgfCAzMy8yLjQ5IHwgMC40NiAoMC4yMi0wLjk4KSB8
2a期临床试验结果显示，特泽利尤单抗在BEC≥150以及FeNO≥25人群中疗效更好_第2页
2a期临床试验结果显示，特泽利尤单抗在BEC≥150以及FeNO≥25人群中疗效更好_第3页
2a期临床试验结果显示，特泽利尤单抗在BEC≥150以及FeNO≥25人群中疗效更好_第4页
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
2a期临床试验结果显示，特泽利尤单抗在BEC≥150以及FeNO≥25人群中疗效更好_第5页
所属报告： 医药行业慢阻肺专题深度：慢病蓝海疗法迭代国产新药BD潜力凸显-250729（30页）.pdf
打包全文图表

相关数据

最新数据
全行业研究报告分享下载平台
  • 0731-84720580
  • 商务合作：really158d
关于我们
更多
关于我们
三个皮匠报告微信公众号
三个皮匠报告微信小程序
扫码咨询网站充值下载问题
copyright@2008-2013 长沙景略智创信息技术有限公司版权所有        网站备案/许可证号：湘B2-20190120 | 工信部备案号：湘ICP备17000430号-2 | 公安备案号：湘公网安备43010402001071号
客服
商务合作
小程序
服务号
折叠